miR-10b Rescues Diabetes and GI Dysmotility Associated with a Leaky Gut
type: CreativeWork
description: Of all microorganisms in the human body, the largest and most complex population resides in the gastrointestinal (GI) tract. The gut microbiota continuously adapts to the host environment and serves multiple critical functions for their hosts, including regulating host immunity, procuring energy from food, and preventing the colonization of pathogens. Mounting evidence has suggested gut immune dysfunction, impaired barrier function, and gut dysmotility play a key role in the development of metabolic disorders and disorders of gut-brain interactions (DGBIs). In reference to the Rome IV criteria, the most common DGBIs, include functional dyspepsia (FD) and irritable bowel syndrome (IBS). Additionally, there is substantial overlap of these disorders and other specific GI motility disorders such as gastroparesis. These disorders are heterogeneous and are intertwined with several proposed pathophysiological mechanisms, such as altered gut motility, intestinal barrier dysfunction, gut immune dysfunction, visceral hypersensitivity, altered GI secretion, presence and degree of bile acid malabsorption, microbial dysbiosis, and alterations to the gut-brain axis. The currently available therapies lack long-term effectiveness and safety for their use to treat motility disorders and DGBIs. Additionally, currently available treatment options simply treat the symptoms and not the pathological mechanism causing the disorder. Pharmacological agents that are developed based on the cellular and molecular mechanisms underlying the pathologies of these disorders might provide the best avenue for future pharmaceutical development. Current advances in RNA-based therapies have substantial promise in treating and preventing many human diseases and disorders through fixing the pathology instead of merely treating the symptomology, like traditional therapeutics. Although many RNA therapeutics have made it to clinical trials, only a few have been FDA-approved thus far. Additionally, the result…
abstract: Of all microorganisms in the human body, the largest and most complex population resides in the gastrointestinal (GI) tract. The gut microbiota continuously adapts to the host environment and serves multiple critical functions for their hosts, including regulating host immunity, procuring energy from food, and preventing the colonization of pathogens. Mounting evidence has suggested gut immune dysfunction, impaired barrier function, and gut dysmotility play a key role in the development of metabolic disorders and disorders of gut-brain interactions (DGBIs). In reference to the Rome IV criteria, the most common DGBIs, include functional dyspepsia (FD) and irritable bowel syndrome (IBS). Additionally, there is substantial overlap of these disorders and other specific GI motility disorders such as gastroparesis. These disorders are heterogeneous and are intertwined with several proposed pathophysiological mechanisms, such as altered gut motility, intestinal barrier dysfunction, gut immune dysfunction, visceral hypersensitivity, altered GI secretion, presence and degree of bile acid malabsorption, microbial dysbiosis, and alterations to the gut-brain axis. The currently available therapies lack long-term effectiveness and safety for their use to treat motility disorders and DGBIs. Additionally, currently available treatment options simply treat the symptoms and not the pathological mechanism causing the disorder. Pharmacological agents that are developed based on the cellular and molecular mechanisms underlying the pathologies of these disorders might provide the best avenue for future pharmaceutical development. Current advances in RNA-based therapies have substantial promise in treating and preventing many human diseases and disorders through fixing the pathology instead of merely treating the symptomology, like traditional therapeutics. Although many RNA therapeutics have made it to clinical trials, only a few have been FDA-approved thus far. Additionally, the result…
author: Zogg, Hannah
keywords: Barrier Dysfunction, DGBIs, Diabetes, GI Dysmotility, Leaky Gut, Metabolic Disorders
date published: 2022
date modified: 2026-07-27T21:46:52Z
provider: University of Nevada - Reno
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: University of Nevada - Reno

PropertyValue
property ID: Handle
value: http://hdl.handle.net/11714/8378